Novelstem International Corp. (NSTM) Stock Price & Analysis
Novelstem International Corp. (NSTM) fell 70.97% to USD 0.01 as of June 10, 2026 at 07:42 UTC, according to Nexqual real-time market data.
NSTM last closed at USD 0.03; the session ranged USD 0.01–0.01 on volume of 57,377 shares. Market capitalization is $443,992, with a 52-week range of USD 0.01–0.04 (PNK). Source: Nexqual, June 10, 2026 at 07:42 UTC.
Key Statistics (as of June 10, 2026 at 07:42 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▼ 70.97% (down) |
| Previous Close | USD 0.03 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0.01 – 0.04 |
| Volume | 57,377 shares |
| Market Cap | $443,992 |
| Exchange | PNK |
Technical Analysis (NSTM)
Nexqual's technical model rates NSTM "BUY" based on 5 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 07:42 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.01) |
| MACD | 0 (positive) |
Analyst Ratings (NSTM)
Wall Street analysts rate NSTM "None", per Nexqual as of June 10, 2026 at 07:42 UTC.
| Consensus Rating | None |
|---|
Earnings (NSTM)
Source: Nexqual, June 10, 2026 at 07:42 UTC.
Financials & Fundamentals (NSTM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.05 |
| Total Cash | $89,850 |
| Total Debt | $1.93M |
| Free Cash Flow | $-964,851 |
Source: Nexqual, June 10, 2026 at 07:42 UTC.
Financial Health Score (NSTM)
Nexqual rates Novelstem International Corp.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:42 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $90K cash vs $2M debt |
| Cash Flow | Weak — FCF negative: -$965K, burning cash |
| Efficiency | Mixed — No data |
Ownership (NSTM)
| Insider Ownership | +58.57% |
|---|---|
| Institutional Ownership | +0.05% |
| Shares Outstanding | 49.33M |
| Float | 19.39M |
| Short % of Float | +0.03% |
Source: Nexqual, June 10, 2026 at 07:42 UTC.
Leadership (NSTM)
Novelstem International Corp. is led by Jan H. Loeb (age 66), Executive Chairman & President, per Nexqual as of June 10, 2026 at 07:42 UTC.
| Executive Chairman & President | Jan H. Loeb (age 66) |
|---|---|
| Co-Founder & Independent Director | Mitchell Rubenstein (age 71) |
| VP, CFO & Secretary | Christine T. Jenkins (age 61) |
From Novelstem International Corp.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of diagnostic technology for cancer treatments and to reduce resistance to chemotherapy.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOAN | Resonate Blends Inc. | USD 0 | ▲ 0% |
| MFON | Mobivity Holdings Corp. | USD 0.08 | ▼ 6.25% |
| RASP | ACTAVIA LIFE SCIENCES INC | USD 0 | ▲ 0% |
| KNBIF | Kane Biotech Inc. | USD 0.03 | ▲ 14.68% |
| NBIO | Nascent Biotech Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:42 UTC. This page is informational and not investment advice.